Story perspectives

Novo Cuts Wegovy U.S. Price 50% Starting 2027

By Drooid · Sep 15, 2026, 3:57 AM UTC · How we work

Summary

Novo Rebrands for Obesity

Novo Nordisk rebranded as ‘Novo’ to revive its obesity-drug market position.
CEO Mike Doustdar, who assumed the role in August 2025, said the change must boost competitiveness.
In Q2 2026, Novo held 38.8% of the obesity market, behind Eli Lilly’s 60.9%.
Novo cut Wegovy’s U.S. list price by 50% starting January 2027.
Oral Wegovy reached three million U.S. prescriptions in five months, generating 3.2 billion kroner in Q2 sales.

Summary

Morgan Stanley Downgrades Novo

Morgan Stanley downgraded Novo Nordisk to Underweight on September 11, 2026, setting a DKK 250 price target.
Novo Nordisk shares have fallen about 15% YTD, trading below 50-day and 200-day averages.
The firm announced a share-buyback programme through February 2027 despite weak stock performance.
Guidance projects adjusted revenue growth between 0% and minus 6% at constant exchange rates.
Novo Nordisk expects lower prices and reduced Medicaid coverage for obesity drugs to pressure earnings.

History

Historical Context

John Eng isolated exendin-4 from Gila-monster venom in 1992 and Amylin licensed it in 1996; the FDA approved the synthetic version, exenatide (Byetta), in April 2005, proving GLP-1 receptor targeting viable. The success spurred rivals—Novo’s semaglutide reached a $570 billion market cap by 2024—fueling the 2026 pricing battles that reflect the competitive pressure after the 2005 launch.

1 of 3

Novo Rebrands for Obesity

Novo Nordisk rebranded as ‘Novo’ to revive its obesity-drug market position.
CEO Mike Doustdar, who assumed the role in August 2025, said the change must boost competitiveness.
In Q2 2026, Novo held 38.8% of the obesity market, behind Eli Lilly’s 60.9%.
Novo cut Wegovy’s U.S. list price by 50% starting January 2027.
Oral Wegovy reached three million U.S. prescriptions in five months, generating 3.2 billion kroner in Q2 sales.

1 / 3